Estimated Societal Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling
Author:
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Neurology
Link
https://link.springer.com/content/pdf/10.1007/s40120-023-00460-1.pdf
Reference47 articles.
1. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020;27(1):18.
2. The Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18(4):700–89.
3. Mank A, van Maurik IS, Rijnhart JJM, Bakker ED, Bouteloup V, Le Scouarnec L, et al. Development of multivariable prediction models for institutionalization and mortality in the full spectrum of Alzheimer’s disease. Alzheimers Res Ther. 2022;14(1):110.
4. Frisoni G. Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools. BMJ Publishing Group Ltd; 2001;711–8.
5. Cummings J, Fox N. Defining disease modifying therapy for Alzheimer’s disease. J Prev Alzheimers Dis. 2017;4(2):109–15.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New International Pharmaco-Economic Collaboration on Alzheimer's Disease (IPECAD) Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer’s Disease Treatment: Development and Use Cases;Value in Health;2024-07
2. New IPECAD open-source model framework for the health technology assessment of early Alzheimer’s disease treatment: development and use cases;2024-04-07
3. Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis;Drug Discovery Today;2024-03
4. Alzheimer’s Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab;The Journal of Prevention of Alzheimer's Disease;2024
5. People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare;Journal of Internal Medicine;2023-12-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3